Pharmacy Service, Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", 750 Salvador Quevedo y Zubieta St., 44340, Guadalajara, Mexico.
Medical and Pharmaceutical Biotechnology Department, Centro de Asistencia en Tecnología y Diseño del Estado de Jalisco, 800 Normalistas Av., 44270, Guadalajara, Mexico.
Pediatr Neonatol. 2020 Jun;61(3):279-289. doi: 10.1016/j.pedneo.2019.11.006. Epub 2019 Nov 22.
Evaluate the type and severity of potential drug-drug interactions and identify risk factors involved, in pediatric patients admitted in a hospital setting.
Transversal retrospective analytical study was carried out with hospitalized pediatric patients from a Hospital in the West of Mexico, second and third level. The patients included were ≤18 years old hospitalized in the children wards; those admitted at the emergency room, neonatal intermediate and intensive therapy units were not included. Medical prescriptions were reviewed taking into consideration anthropometric characteristics, diagnosis and number of drugs prescribed to identify potential drug-drug interactions using Micromedex 2.0 database.
88 patients were included, an average of 4.6 ± 2.8 of drugs were prescribed per patient. 37 subjects (42%) presented some degree of potential drug-drug interactions of which 25.5% were major and 27.7% moderate according to the software. Identified risk factors were: age ≥ 4 years (OR 1.917; 95% CI 1.081-3.399), BSA ≥ 0.8m2(OR 1.825; 95% CI 1.021-3.263), height ≥ 1 m (OR 2.556;95% CI 1.322 - 4.941), and number of prescribed medications ≥ 4 (OR 2.106;95% CI 1.248 - 3.556).
Some of the interactions found were for the benefit of the patient, but others were considered undesirable because they altered the pharmacokinetics of some of the medications administered. Detecting in time the harmful interactions for a patient may favor the patient's safety.
评估儿科住院患者潜在药物相互作用的类型和严重程度,并确定涉及的风险因素。
对墨西哥西部一家医院的住院儿科患者进行了一项横断面回顾性分析研究。纳入的患者为≤18 岁,在儿科病房住院;不包括在急诊室、新生儿中级和强化治疗病房住院的患者。考虑到患者的人体测量特征、诊断和开具的药物数量,审查了医疗处方,以使用 Micromedex 2.0 数据库识别潜在的药物相互作用。
共纳入 88 例患者,每位患者平均开具 4.6±2.8 种药物。37 名患者(42%)存在某种程度的潜在药物相互作用,根据软件,其中 25.5%为主要相互作用,27.7%为中度相互作用。确定的风险因素为:年龄≥4 岁(OR 1.917;95%CI 1.081-3.399)、BSA≥0.8m2(OR 1.825;95%CI 1.021-3.263)、身高≥1m(OR 2.556;95%CI 1.322-4.941)和开具的药物数量≥4 种(OR 2.106;95%CI 1.248-3.556)。
虽然有些相互作用对患者有益,但也有些相互作用被认为是不理想的,因为它们改变了一些药物的药代动力学。及时发现对患者有害的相互作用可能有利于患者的安全。